Lead Product(s) : Opiranserin Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
VIVOZON Wins MFDS Nod for UNAFRA Inj., a Breakthrough Non-Opioid Analgesic
Details : Unafra (opiranserin HCl) induces analgesic effect by simultaneously inhibiting GlyT2 and 5HT2a, thereby blocking pain signals and transmission synergistically across nervous systems.
Product Name : Unafra
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 18, 2025
Lead Product(s) : Opiranserin Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable